Skip to main content

Pharma RSS Digest - 2026-05-26

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The digest window was light, featuring only two substantive company-specific catalysts. Sentire® Surgical System's EU CE Mark approval gives Cornerstone Robotics a clear path into a major market, while Hansa Biopharma's upcoming data presentation at ATC could influence a December FDA decision for imlifidase. Neither story signals broader sector themes; the tape reflects discrete regulatory and clinical milestones rather than macro-driven moves.

Key Developments​

Cornerstone Robotics gains EU entry with Sentire® system

Sentire® Surgical System fda approval update

Cornerstone Robotics announced its Sentire® Endoscopic Surgical System received EU CE Mark under the Medical Device Regulation, covering general surgery, gynecology, thoracic, and urology. The company has built operational infrastructure in the UK, completed a validation study with Portsmouth Hospitals University NHS Trust, and raised roughly $200 million in November 2025. The CE Mark unlocks EU commercial access while the UK clinical work provides real-world evidence to support surgeon adoption and reimbursement discussions. What remains unconfirmed is the timing of the EU launch and the scope of reimbursement coverage. Watch for the commercial launch timeline and any peer-reviewed publication of the UK case data.

Hansa Biopharma clinical trial update

Hansa Biopharma to present ConfIdeS 12-month data at ATC

Hansa Biopharma said 12-month results from its Phase 3 ConfIdeS trial in kidney transplantation will be presented as a late-breaking oral abstract at the American Transplant Congress on June 22. Dr. Robert Montgomery of NYU Langone will present eGFR primary endpoint and secondary endpoint data for highly sensitized patients treated with imlifidase. The FDA is already reviewing the BLA with a PDUFA date of December 19, 2026. Positive data could reinforce the approval case and support broader adoption among transplant centers. Full statistical significance and safety details have not yet been disclosed. Watch for the presentation and whether the data signals a differentiated profile on eGFR preservation.